Image of 96-well transwell plate


InflammaScreenTM Services

Rapidly screen for anti-inflammatory leads using Repligut® Planar

Inflammatory bowel diseases (IBD) are a major health concern worldwide, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects.

A major reason successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.

That's why we developed InflammaScreen™ Services, a suite of pre-qualified, multiple readout assays using our flagship model RepliGut® Planar Transverse Colon.  These assays are specifically designed to both speed up discovery and improve the human relevance of gastrointestinal inflammation focused drug discovery. 

Ways to benefit from an InflammaScreen Study


Triage larger chemical sets to identify most promising candidates


Compare candidates to gain clarity on overlapping or discerning functionalities


Achieve fast iterative turnaround while optimizing structure and function


Save money and time by eliminating ineffective molecules early

How it works

With RepliGut® Planar, stem cells from intestinal crypts are proliferated as a monolayer and matured into a fully differentiated epithelium using RepliGut® Maturation Media (RMM).  After 2 days in maturation medium, the model is treated with TNF-α in the presence or absence of test articles.  The tissue is monitored for barrier integrity using TEER and evaluated for quantitative cytotoxicity and IL-8 release after 48 hours.

Experimental Timeline

Experimental Timeline updated no header
InflammaScreen Infographic-10


  1. 1.   Cultures are pre-treated with your compounds.
  2. 2.   Pro-inflammatory cytokine TNF-a is added to initiate damage.
  3. 3.   TEER measurements are taken at 24- and 48-hours post-treatment; LDH and IL8 measurements are taken at 48 hours post-treatment.



Data Output

You receive both raw data files and graphs with statistics for each of your compounds tested against a low and high level exposure to TNF-α.  Data shown here shows block of TNF-α effects using Adilumimab (Humira®).  Adalumimab is included as positive control on each InflammaScreen™ plate
InflammaScreen Data-11

Getting Started



Start your project and ship compounds to Altis



Test up to 10 compounds per plate for anti-TNF signaling phenotypes


Get Results

Our experienced project leads get your results to you in as little as 3 weeks

Results from InflammaScreen™ Services will give you clinically relevant insights into how your test drugs will interact with the inflamed intestinal epithelium using a standard format with rapid turnaround times

Begin your design

View and download the Inflammascreen 96-well platemap to start designing your experiment. Our project leads are available to support you throughout

The ability to test for anti-inflammation is more accessible than ever
Schedule your consultation with our experts today